Shahzad Ilyas

Papers

Total Citations

H-Index

About

Dr. Shahzad Ilyas is a distinguished urologic oncologist whose research focuses on advancing minimally invasive treatments for renal cell carcinoma (RCC), particularly through comparative effectiveness studies. His landmark 2016 study, "Percutaneous Radiofrequency Ablation Versus Robotic-Assisted Partial Nephrectomy for the Treatment of Small Renal Cell Carcinoma," with 62 citations, systematically compared oncologic outcomes between radiofrequency ablation (RFA) and robotic-assisted partial nephrectomy (RPN) for T1 stage RCC. By retrospectively analyzing data from a high-volume single tertiary center, Dr. Ilyas provided critical evidence guiding clinical decision-making for small renal masses, demonstrating that both modalities offer effective cancer control while highlighting their respective advantages in morbidity and recovery. This work has significantly influenced urologic practice by clarifying the role of thermal ablation as a viable alternative to surgery in appropriately selected patients. Dr. Ilyas’s contributions extend beyond this study, as his research portfolio consistently addresses the optimization of nephron-sparing approaches, balancing oncologic efficacy with quality-of-life outcomes. His rigorous methodology and clinically relevant findings have made him a respected voice in urologic oncology, particularly among researchers and clinicians seeking evidence-based strategies for managing early-stage kidney cancer.